Literature DB >> 32814341

COVID-19 and remdesivir in pediatric patients: the invisible part of the iceberg.

Nadir Yalçın1, Kutay Demirkan2.   

Abstract

Entities:  

Year:  2020        PMID： 32814341     DOI： 10.1038/s41390-020-01109-7

Source DB:  PubMed          Journal:  Pediatr Res        ISSN： 0031-3998            Impact factor:   3.756


× No keyword cloud information.
  1 in total

1.  First Newborn Baby to Receive Experimental Therapies Survives Ebola Virus Disease.

Authors:  Jenny Dörnemann; Chiara Burzio; Axelle Ronsse; Armand Sprecher; Hilde De Clerck; Michel Van Herp; Marie-Claire Kolié; Vesselina Yosifiva; Severine Caluwaerts; Anita K McElroy; Annick Antierens
Journal:  J Infect Dis       Date:  2017-01-15       Impact factor: 5.226
  1 in total
  3 in total

1.  SARS-CoV-2 Associated Respiratory Failure in a Preterm Infant and the Outcome after Remdesivir Treatment.

Authors:  Mohammed A Sarhan; Maria Casalino; Pongsatorn Paopongsawan; David Gryn; Tapas Kulkarni; Ari Bitnun; Estelle B Gauda
Journal:  Pediatr Infect Dis J       Date:  2022-05-01       Impact factor: 3.806

Review 2.  Remdesivir: the first FDA-approved anti-COVID-19 Treatment for Young Children.

Authors:  Alexandra Chera; Antoanela Tanca
Journal:  Discoveries (Craiova)       Date:  2022-06-30

Review 3.  Therapeutic Strategies for COVID-19 Lung Disease in Children.

Authors:  Elisabetta Gatti; Marta Piotto; Mara Lelii; Mariacarola Pensabene; Barbara Madini; Lucia Cerrato; Vittoria Hassan; Stefano Aliberti; Samantha Bosis; Paola Marchisio; Maria Francesca Patria
Journal:  Front Pediatr       Date:  2022-03-07       Impact factor: 3.418
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.